Fig. 1From: A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammationPlasma levels of SFN and its major metabolites SFN-N-acetylcysteine and SFN-glutathione following BSH supplementation (a). O3-induced changes in sputum neutrophil counts with placebo or SFN supplementation (N = 14) (b). Changes are presented as PMNs/mg sputum and %PMNs/mg sputumBack to article page